Eliem Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ELYM research report →
About the company
Eliem Therapeutics, Inc. is a clinical-stage biotechnology firm focused on developing therapeutic solutions for conditions characterized by abnormal neuronal excitability. The company aims to fulfill significant unmet medical needs in areas such as chronic pain management, neuropsychiatric illnesses, epilepsy, and other disorders affecting the central and peripheral nervous systems.
- CEO
- Aoife M. Brennan BAO, BCh, MB, MMSc
- IPO
- 2021
- Employees
- 9
- HQ
- Redmond, WA, US
Price Chart
- Market Cap
- $342.68M
- P/E
- -16.67
- P/S
- 0.00
- P/B
- 5.94
- EV/EBITDA
- -16.55
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -31.46%
- ROIC
- -40.44%
- Revenue
- $0 · 0.00%
- Net Income
- $-59,851,000 · 19.01%
- EPS
- $-0.88 · 42.48%
- Op Income
- $-67,883,000
- FCF YoY
- -250.48%
- 52W High
- $11.55
- 52W Low
- $2.35
- 50D MA
- $6.46
- 200D MA
- $5.57
- Beta
- -0.38
- Avg Volume
- 519.72K
Get TickerSpark's AI analysis on ELYM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 18, 24 | Pimblett Emily | other | 5,000 |
| Sep 18, 24 | Pimblett Emily | other | 5,000 |
| Sep 20, 24 | Pimblett Emily | sell | 1,182 |
| Sep 20, 24 | Pimblett Emily | sell | 9 |
| Aug 26, 24 | Kaplan Brett | other | 465,000 |
| Aug 26, 24 | Kaplan Brett | other | 77,500 |
| Aug 26, 24 | Kaplan Brett | other | 0 |
| Jul 19, 24 | Morisset Valerie | sell | 10,201 |
| Jul 19, 24 | Morisset Valerie | sell | 50,000 |
| Jul 22, 24 | Morisset Valerie | sell | 39,005 |
Our ELYM coverage
Recent articles, reports, and earnings notes.
No research on ELYM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ELYM report →Similar companies
Peers in the same neighborhood.